StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

1,2-Diphenyl-4-(2-(phenylsulfi-nyl)ethyl)-3,5-pyrazolidindion

Sulfinpyrazone

HCID 5342
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
57-96-5
Standard-SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
Summenformel
C23H20N2O3S
Durchschnittliche Molmasse
404,5 g/mol
Monoisotopische Masse
404,11946368

Überblick

Sulfinpyrazone is a sulfoxide and a member of pyrazolidines. It has a role as a uricosuric drug.

Namen und Bezeichner

Bevorzugter Name
Sulfinpyrazone
IUPAC
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
Lokaler Name
1,2-Diphenyl-4-(2-(phenylsulfi-nyl)ethyl)-3,5-pyrazolidindion
Englischer Name
(+/-)-Sulfinpyrazone
Summenformel
C23H20N2O3S
Molmasse
404.48

Namen und Synonyme

sulfinpyrazone57-96-5SulphinpyrazoneAnturaneAnturanDiphenylpyrazoneSulfoxyphenylpyrazolidineSulfinpyrazonAnturidinEnturenAnturanil1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione
Weitere Namen anzeigen
g28315anturenenturang28,315
AnturanoUSAF GE-13SulfinpirazonaSulfinpyrazonum4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dioneDTXSID00236184-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione

Datenbank-Bezeichner

CAS
57-96-5
PubChem CID
5342
DTXSID
DTXSID0023618
ChEMBL
CHEMBL832
ChEBI
CHEBI:9342
UNII
V6OFU47K3W
EC Number
200-357-4
Nikkaji

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,3
Polarare Oberfläche (TPSA)
76,9 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
6
Schwere Atome
29
Formalladung
0
Komplexität
571

Experimentelle und physikochemische Eigenschaften

LogP · 2 Einträge

2.4

3.56

Color/FormWHITE TO OFF-WHITE
Solubility · 5 Einträge

SOL IN ETHYL ACETATE, CHLOROFORM

SLIGHTLY SOL IN WATER, ALC, ETHER, MINERAL OILS

SLIGHTLY SOL IN FATS

1 G SOL IN 10 ML ACETONE & 10 ML 0.5 N NAOH

For more Solubility (Complete) data for SULFINPYRAZONE (6 total), please visit the HSDB record page.

Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 4 Einträge

136-137 °C

136-137 °C

MELTING POINT: 130-133 °C /D-FORM, L-FORM/

136 - 137 °C

Physical DescriptionSolid
Stability/Shelf LifeSTABLE TO LIGHT & AIR
Dissociation Constants

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 70 reports by companies from 1 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Interactions · 3 Einträge

...URICOSURIC ACTION /OF SULFINPYRAZONE/ IS ADDITIVE TO THAT OF PROBENECID & PHENYLBUTAZONE BUT IS MUTUALLY ANTAGONISTIC TO THAT OF SALICYLATES. ... POSSESSES ABILITY TO DISPLACE OTHER ORG ANIONS THAT ARE BOUND EXTENSIVELY TO PLASMA PROTEINS...THUS ALTERING THEIR DISTRIBUTION TO TISSUES & THEIR RENAL EXCRETION...

...SULFINPYRAZONE MAY POTENTIATE ACTIONS OF INSULIN & ORAL HYPOGLYCEMIC AGENTS...

SULFINPYRAZONE MAY DISPLACE SULFONAMIDES FROM PLASMA PROTEIN BINDING SITES...

Human Toxicity Excerpts · 2 Einträge

HYPERSENSITIVITY REACTIONS, USUALLY A RASH WITH FEVER, DO OCCUR.../OCCASIONALLY/

SIDE EFFECTS INCL UPPER GI DISTURBANCES...&, RARELY, ANEMIA, LEUKOPENIA, AGRANULOCYTOSIS, & THROMBOCYTOPENIA.

Sicherheitsdaten

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding98-99%
Pharmacodynamics · 1 Eintrag

Sulfinpyrazone's pharmacologic activity is the potentiation of the urinary excretion of uric acid. It is useful for reducing the blood urate levels in patients with chronic tophaceous gout and acute intermittent gout, and for promoting the resorption of tophi.

Mechanism of Action · 2 Einträge

Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).

...IN SUFFICIENT DOSAGE IS POTENT INHIBITOR OF RENAL TUBULAR REABSORPTION OF URIC ACID. ...SMALL DOSES MAY REDUCE EXCRETION...PRESUMABLY BY INHIBITING SECRETORY BUT NOT REABSORPTIVE TRANSPORT. BY COMPETITIVE INHIBITION...REDUCES RENAL TUBULAR SECRETION OF OTHER ORG ANIONS...AS PAH /PARA-AMINOHIPPURIC/ & SALICYLIC ACID.

Biological Half-LifeApproximately 4-6 hours
Metabolism/Metabolites · 3 Einträge

MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS N1-P-HYDROXYPHENYL METABOLITE...

.../IN RAT/ 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE.

Zugehörige Reaktionen

6
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 156978
HRID 156978als Produkt
Reaktionsgleichung von HRID 833034
HRID 833034als Edukt
Reaktionsgleichung von HRID 1577634
HRID 1577634als Produkt
Reaktionsgleichung von HRID 1577636
HRID 1577636als Produkt
Reaktionsgleichung von HRID 1577637
HRID 1577637als Produkt
Reaktionsgleichung von HRID 1719691
HRID 1719691als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
J1.384F
· 2 Einträge

3.25

PKA: 2.8

Collision Cross Section · 2 Einträge

193.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

193.18 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Other Experimental Properties · 3 Einträge

CRYSTALS FROM CHLOROFORM & HEPTANE; CRYSTALS FROM ETHANOL /D-FORM/; CRYSTALS /L-FORM/

SPECIFIC OPTICAL ROTATION: +67.1 DEG @ 22 °C/D (C= 2.04 IN ETHANOL); +109.3 DEG @ 25 °C/D (C= 0.5 IN CHLOROFORM) /D-/

SPECIFIC OPTICAL ROTATION: -64.2 DEG @ 23 °C/D (C= 2.14 IN ETHANOL); -104.5 DEG @ 26 °C/D (C= 0.5 IN CHLOROFORM) /L-/

Physikochemische Eigenschaften

Schmelzpunkt
136 · 136-137°
Siedepunkt
590.8 · 590.8±42.0 °C(Predicted)
Dichte
1.189 · 1.1890 (rough estimate)
Brechungsindex
1.636 · 1.6360 (estimate)
storage temp.
Sealed in dry,Room Temperature
Löslichkeit
Very slightly soluble in water, sparingly soluble in ethanol (96 per cent). It dissolves in dilute solutions of alkali hydroxides.
Aggregatzustand
Solid
pka
2.8 · pKa 2.8(H2O t = RT I undefined) (Uncertain)
Farbe
Off-White to Light Brown
Wasserlöslichkeit
2.601 g/L · 2.601g/L(22 ºC)
Major Application
cleaning productscosmeticsfood and beveragesforensics and toxicologypersonal carepharmaceutical (small molecule)veterinary
InChI
1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4
CAS Datenbank
57 · 57-96-5(CAS DataBase Reference)
NIST chemische Informationen
Sulfinpyrazone(57-96-5)
wgk
3
hs_code
2933194350
RTECS-Nr.
UQ8575000
risk_code
22
hazard_code
Xn
safety_code
36
Speicherklasse
11 - Combustible Solids
Giftige Stoffe Daten
57-96-5(Hazardous Substances Data)
Hazard Classifications
Acute Tox. 4 Oral

Sulfinpyrazone has known human metabolites that include Sulfinpyrazone sulfone.

MeSH Pharmacological ClassificationGout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
Absorption, Distribution and Excretion · 5 Einträge

...WELL ABSORBED AFTER ORAL ADMIN. ...BOUND TO PLASMA PROTEINS...98-99%. T/2... IN PLASMA AFTER IV INJECTION IS ABOUT 3 HR. AFTER ORAL ADMIN...URICOSURIC EFFECT MAY PERSIST FOR...10 HR. ALTHOUGH LITTLE...IS AVAILABLE FOR FILTRATION @ GLOMERULUS, IT IS SECRETED BY PROXIMAL TUBULE & UNDERGOES LITTLE PASSIVE BACK DIFFUSION...

APPROX HALF OF ORALLY ADMIN DOSE APPEARS IN URINE WITHIN 24 HR. MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS...METABOLITE...

...RAPIDLY EXCRETED IN MAN, TOGETHER WITH P-HYDROXYLATED METABOLITE. PLASMA T/2...IN RATS...16.2 HR, &...18% OF IP DOSE...WAS EXCRETED INTO URINE. PLASMA T/2 IN MAN...BETWEEN 1 & 3 HR. MAIN ROUTE OF ELIMINATION IN RAT...FECES (68% OF DOSE)...CONSIDERABLE PORTION...EXCRETED IN BILE WAS REABSORBED FROM INTESTINAL TRACT.

...SULFINPYRAZONE...IS EXCRETED IN URINE OF RATS TO ONLY A SMALL EXTENT. ... CLEARED FROM CIRCULATION MAINLY THROUGH BILE...NO EVIDENCE OF ENTERO-HEPATIC CIRCULATION MECHANISM.

UNCHANGED DRUG /IN RAT/ WAS PRINCIPAL EXCRETION PRODUCT & ONLY 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE. FAILURE OF RAT TO EXCRETE A HIGH PROPORTION OF THE DRUG IN URINE MAY BE RELATED TO ITS LACK OF URICOSURIC PROPERTIES IN THIS SPECIES.

Cellular LocationsCytoplasm

Verwendung und Herstellung

UsesMEDICATION
Methods of Manufacturing · 2 Einträge

SYNTHESIS: PFISTER, HAFLIGER, HELV CHIM ACTA 44, 232 (1961).

[2-(PHENYLSULFINYL)ETHYL]MALONIC ACID DIETHYL ESTER IS CONDENSED WITH HYDRAZOBENZENE WITH AID OF SOLN OF SODIUM ETHOXIDE IN ABSOLUTE ETHANOL. ... /ADDN/ XYLENE & HEATING @...130 DEG...ETHANOL...IS REMOVED. SULFINPYRAZONE IS ISOLATED BY SOLVENT EXTRACTION...& RECRYSTALLIZED FROM ETHANOL. US PATENT 2,700,671.

Formulations/PreparationsANTURANE (GEIGY). ORAL: CAPSULES 200 MG; TABLETS 100 MG.
Anwendungen · 2 Einträge

BeschreibungSulfinpyrazone is soluble in alkaline solutions. Its synthesis is similar to that of phenylbutazone (Fig. 36.33). It produces its uricosuric effect in a manner similar to that of probenecid. A dose of 35 mg produces a uricosuric effect equivalent to that produced by 100 mg of probenecid, whereas 400 mg/day of sulfinpyrazone produces an effect comparable to that obtained with doses of 1.5 to 2 g of probenecid. It also possesses, not surprisingly, some of the properties of phenylbutazone. It is an inhibitor of human platelet prostaglandin synthesis at the cyclooxygenase step, resulting in a decrease in platelet release and a reduction in platelet aggregation. This antiplatelet effect suggests a role for sulfinpyrazone in reducing the incidence of sudden death, which can occur in the first year following a myocardial infarction; however, it lacks the analgetic and anti-inflammatory effects of phenylbutazone.

VerwendenAs an anti-inflammatory and uricosuric agent, its side effects were severe enough to preclude its continuous use in the treatment of chronic gout. Evaluation of several chemical congeners indicated that the phenylthioethyl analog of phenylbutazone had promising anti-inflammatory and uricosuric activity. A metabolite, the sulfoxide pyrazone, exhibited enhanced uricosuric activity. Interestingly, the corresponding sulfone does not appear to be a metabolite. Sulfinpyrazone lacks the clinically striking anti-inflammatory and analgesic properties of phenylbutazone.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

NatriumPeroxomonoschwefelsure1,2-Diphenyl-4-(2-(phenylthio)-ethyl)-3,5-pyrazolidindionNatriumhydrogencarbonatEthylacetatNatriumhydrogensulfitEssigsureToluol